Google
ENGN 株価分析 — Engene Holdings Inc. Common Stock (Healthcare >> Biotechnology)
ENGN に関するよくある質問
ENGNのPER（株価収益率）は？
Engene Holdings Inc. Common Stock（ENGN）は現在PER 3.92倍で取引されています。
ENGNのROE（自己資本利益率）は？
Engene Holdings Inc. Common StockのROEは-26.02%です。
ENGNの配当利回りは？
Engene Holdings Inc. Common Stockの配当利回りは0.00%です。
ENGNの品質スコア（Quality Score）は？
当社のAIはENGNの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ENGNは今が買い時ですか？
当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ENGNはどのセクターに属しますか？
Engene Holdings Inc. Common StockはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
ENGN AI Analysis Summary
Our AI summary for ENGN: Engene Holdings Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 3.92, ROE of -26.02%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.79
Price
0.02
(1.13%)
Day Change
|
|
|---|
ENGN, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.79 |
| PBV / Sector |
0.46 / 44,022.72
GREAT
|
| Earning Per Share | -1.00 |
| PE / Sector |
3.92 / 19.17
GREAT
|
| PEG or PE/Growth / Sector |
0.06 / 1.24
GREAT
|
| Average 1M Daily Value |
1.54 M
GREAT
|
| Average 1W Daily Value |
0.98 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:08 |
| Symbol | ENGN |
| Name | ENGENE HOLDINGS INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 66.99 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 118.57 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4868 Rue Levy, Montreal, QC, Canada, H4R 2P1
Phone: 514 332 4888
Website: https://www.engene.com
Employees: 81
Sector: Healthcare >> Biotechnology
Description: enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
